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Background: We performed a multicenter evaluation of the Elecsys® progastrin-releasing peptide (ProGRP)
immunoassay in Europe and China.
Methods: The assay was evaluated at three European and two Chinese sites by imprecision, stability, method
comparison and differentiation potential in lung cancer.
Results: Intermediate imprecision across ﬁve analyte concentrations ranged from 2.2% to 6.0% coefﬁcient of
variation. Good stability for plasma and serum samples was shown for various storage conditions. There was
excellent correlation between the Elecsys® and ARCHITECT assays in plasma (slope 1.02, intercept
−2.72 pg/mL). The Elecsys® assay also showed good correlation between serum and plasma samples (slope
0.93, intercept 2.35 pg/mL; correlation coefﬁcient 0.97). ProGRP differentiated small-cell and non-small-cell
lung cancer (NSCLC; area under the curve 0.90, 95% CI 0.87–0.93; 78.3% sensitivity, 95% speciﬁcity; at
84 pg/mL), with no relevant effects of ethnicity, age, gender or smoking. Median ProGRP concentrations were
low in benign diseases (38 pg/mL), other malignancies (40 pg/mL) or NSCLC (39 pg/mL), except chronic kidney
disease above stage 3 (N100 pg/mL).
Conclusions: Increased stability of the Elecsys® ProGRP assay in serum and plasma offers clear beneﬁts over
existing assays. This ﬁrst evaluation of a ProGRP assay in China demonstrated comparable differentiation
potential among different ethnicities.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).LC, small-cell lung cancer; NSE,
peptide; NET, neuroendocrine
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Tumor markers have been extensively studied in patients with lung
cancer as a means to differentiate between the two major subtypes of
lung cancer—non-small-cell lung cancer (NSCLC) and small-cell lung
cancer (SCLC)—and, thereby, improve diagnosis and treatment selection
[1–5]. NSCLC accounts for around 80% of all new lung cancer cases, with
SCLC making up the remaining 20%. SCLC differs from NSCLC in having
neuroendocrine differentiation, a higher tumor growth rate and earlier
development of metastasis [6,7], and as such requires a different treat-
ment approach. Of the two subtypes, NSCLC is more likely to present
at an early stage, when surgery offers the best chance of cure [8]. The
early-stage diagnosis of SCLC is very rare, meaning surgery is uncom-
mon, but SCLC is highly sensitive to radiotherapy and chemotherapy
[7]. Patients with SCLC often relapse; however, and 5-year survivalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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nosis of lung cancer subtype at initial presentation is critical to ensure
appropriate therapeutic intervention.
Tumor biopsies are an essential component in the histologic differ-
entiation of lung cancer. However, because of the submucosal location
of many SCLCs, accurate tissue sampling can be difﬁcult, and biopsies
do not allow for early detection of the disease [10]. When diagnosed
with limited-stage disease, approximately 20% of patients with SCLC
can achieve long-term survival with aggressive chemotherapy and
radiotherapy, versus just 5% when diagnosed at an advanced stage
[10]. The analysis of tumor markers in plasma or serum samples offers
clear beneﬁts over histologic differentiation, including the potential
for early detection of SCLC, and the chance to improve survival rates.
Neuron-speciﬁc enolase (NSE) and progastrin-releasing peptide
(ProGRP) have proved most beneﬁcial as tumor markers in SCLC [11,
12]. Although NSE was historically the recommended tumor marker
for SCLC [13], NSE also stains up to 80% of NSCLCs in tissue examinations
and is elevated in the sera of 20–30% of patients with NSCLC [14].
Furthermore, NSE has low sensitivity, particularly in patients with
disease conﬁned to the hemithorax or ipsilateral mediastinum [15]. As
NSE is present in platelets and erythrocytes, samples with hemolysis
must be excluded and rapid storage of samples is essential [14]. ProGRP
accurately discriminates between NSCLC and SCLC [16,17] and is rarely
elevated in other malignant diseases or in benign conditions, except in
patients with renal insufﬁciency, neuroendocrine tumors (NET) of the
lung and medullary carcinoma of the thyroid (MCT) [16–22].
Evaluation of the ﬁrst fully automated ProGRP ARCHITECT assay
(Abbott Laboratories, Wiesbaden, Germany) was reported in 2009
[23]. Owing to the poor stability of ProGRP in serum on the
ARCHITECT assay, which is believed to be due to thrombin-induced
proteolysis, plasma samples are the recommended source material
[24,25]. The Elecsys® ProGRP assay (Roche Diagnostics GmbH,
Penzberg, Germany) is a new immunoassay designed to quantitatively
determine levels of ProGRP in both human serum and plasma. As the
two monoclonal antibodies in the Elecsys® ProGRP assay bind to
epitopes in the ProGRP peptide that are relatively resistant to
endoproteolytic cleavage [16,17,26] (Supplementary Fig. S1), serum
samples as well as plasma samples can be used. Here we report on the
technical and clinical performance of the Elecsys® ProGRP assay across
a number of European and Chinese sites.
2. Materials and methods
Between August 2012 and September 2013, the Elecsys® ProGRP
assay was evaluated at three European investigational sites in
Amsterdam, Barcelona and Bonn, and two Chinese sites in Beijing
(Peking Union Medical College Hospital [PUMCH] and Peking Xuanwu
Hospital). Ethical approval/waiver was obtained from each institution
before clinical study work began. All investigational sites conducted
the study in accordance with the Declaration of Helsinki (rev. Tokyo,
Venice, Hong Kong and Fortaleza 2013) and International Conference
on Harmonisation Good Clinical Practice guidelines. The objective of
the study was to evaluate the performance of the Elecsys® ProGRP
assay in terms of imprecision, stability, method comparison and differ-
entiation potential for SCLC.
2.1. Assay description
The Elecsys® ProGRP assay is an electrochemiluminescence immu-
noassay that uses a biotinylated ProGRP-speciﬁc mouse monoclonal
antibody and a ruthenium-labeled ProGRP-speciﬁc mouse monoclonal
antibody to capture and detect ProGRP in human serum and plasma.
The assay is calibrated using the ProGRP CalSet (Roche Diagnostics)
and has been standardized against the ARCHITECT ProGRP assay.
Quality control is performed using two levels of PreciControl ProGRP(Roche Diagnostics). Both the calibrator and the control contain recom-
binant ProGRP.
2.2. Sample sources, preparation and handling
Samples were sourced from patients with previously untreated
active disease, who had sufﬁcient samplematerial available for analysis.
No further demographic or histologic selection criteria were utilized.
Lung cancer histologic types were classiﬁed according to the 1999
World Health Organization recommendations [27]. Differential diagno-
sis between SCLC and NSCLC was based on morphologic characteristics
plus a positive CD56 and/or synaptophysin immunohistochemistry of
the tumor. Lung cancer staging (TNM) was established according to
international guidelines [28].
All sites collected samples and performed assay measurements. An
additional German site (Institut für Klinische Pharmakologie GmbH,
Kiel) contributed samples from apparently healthy individuals as a
reference cohort. Owing to the low prevalence of SCLC in the patient
population, differential diagnosis was based primarily on patient
serum samples sourced from sample banks in Europe, whereas samples
were collected prospectively in China (January to September 2013).
All three European sites and PUMCH used serum for clinical evalua-
tion. Xuanwu used K2-EDTA primary tubes for plasma collection. The
stability experiment was performed in Bonn and Amsterdam using
K2-EDTA and serum separation tubes (SSTs). In addition, Amsterdam
used rapid serum tubes (RSTs) for serum sampling in this experiment.
The interior wall of the RSTs was coated with thrombin to promote
rapid clotting. All studies were performed on cobas® e411 and e601
analyzers.
2.3. Statistical analyses
All analytical data were captured using the WinCAEv (Windows-
based computer aided evaluation) software program. Demographic
and clinical data were collected using the MACRO software program.
All statistical analyses using clinical information were performed in
the biostatistics department at Roche Diagnostics Penzberg using SAS
(Statistical Analysis Software, version 9.2) and R (version 2.13.2).
Outliers identiﬁed by visual inspection of the primary data set were
re-measured.
2.4. Technical assessment
2.4.1. Interlaboratory survey
Three EDTA plasma sample pools were prepared by Roche R&D
(~30, ~200 and ~1500 pg/mL) and distributed to all ﬁve investigational
sites to evaluate differences in recovery and day-to-day variability
between the laboratories in these three concentration ranges. The two
levels of PreciControl ProGRP were also used as sample material. Each
sample was measured in single determination over 10 days in each
laboratory. The percentage recovery per sample was calculated as the
measured concentration/all laboratory median ×100.
2.4.2. Imprecision according to clinical laboratory and standards institute
EP5-A2
Imprecision was assessed by means of the Clinical Laboratory and
Standards Institute (CLSI) EP5-A2 guideline [29]. Three sample pools
were prepared by each of the European sites with speciﬁed
target concentration ranges of 7–60 pg/mL, 61–1000 pg/mL and
1001–5000 pg/mL. Approximately 27 mL of serum or plasma was
required to prepare 84 × 300 μL aliquots. Samples were stored at
−20 °C and used on the respective day of measurement. Repeatability
and intermediate precision estimates were obtained by modeling the
data according to the CLSI EP5-A2 variance component model.
Between-day, between-run and repeatability variance components
390 C.M. Korse et al. / Clinica Chimica Acta 438 (2015) 388–395were modeled. The intermediate precision estimate was given as the
coefﬁcient of variation (CV) based on the total variance estimate.
2.4.3. Stability of sample material
Matched serum and plasma specimens were obtained from patients
who provided written informed consent, with approval of the institu-
tional review board. The concentration of ProGRP in the samples was
ideally to exceed 100 pg/mL; however, some samples below this
concentration were included as it proved difﬁcult to obtain informed
consent and samples. A minimum of 3 mL each of serum and plasma
was required per patient to prepare nine 300 μL aliquots. Measurements
were performedwithin 1 h of sampling for baselinedeterminations, and
after 1, 2, 3 and 4 hours at room temperature and 3, 6, 24 and 48 hours
at 2–8 °C.Measurementswere ﬁrst taken on theARCHITECT instrument
and then, within 30 minutes, on the cobas® instrument. Serum
and plasma were tested within the same run. The percentage
recoverywas calculated as the actual concentration/baseline concentra-
tion ×100.
2.4.4. Method comparison
Comparisons were obtained with the ARCHITECT ProGRP assay and
the Fujirebio microtiter plate enzyme-linked immunosorbent ProGRP
assay (Fujirebio Diagnostics, Japan). Ideally, plasma samples were to
be used for the ARCHITECT instrument and serum samples for the
Fujirebio assay. Deming regression with an error ratio of 1 was used
for the estimation of the regression lines [30]. Conﬁdence intervals
(CIs) for intercept and slope were obtained via the bootstrap method
[31].
2.4.5. Matrix comparison
Matched serum and plasma specimens were collected from routine
samplings between Q3 2012 and Q1 2013 and frozen until batch-wise
measurement in Q1 2013. Samples were collected over several weeks
to attempt to cover the entire measuring range (3–5000 pg/mL).
3. Clinical assessment
3.1. Reference range determination
For the ProGRP reference range calculation, healthy cohorts were
compared from theﬁve European and two Chinese sites, plus the cohort
of apparently healthy individuals recruited from the Kiel site according
to their responses to a health check questionnaire and results of basic
clinical chemistry parameters, such as glucose, cholinesterase, creati-
nine, C-reactive protein and hemoglobin levels. Three specimen types
were collected at the Kiel site: serum, K2-EDTA plasma and Li-Heparin
plasma. Samples from Kiel were stored at−80 °C in the sample bank
at Roche Penzberg and measured in Bonn. Amsterdam, Barcelona and
Bonn collected serum samples only. PUMCH in China collected serum
and K3-EDTA plasma samples, and Xuanwu collected K2-EDTA plasma
samples only. Quantiles were calculated with the type = 3 method in
the R software. The CIs were nonparametric with regard to the method
of Hahn and Meeker [32].
3.2. Differential diagnosis
The malignant cohorts of NSCLC and SCLC were the primary focus,
with control cohorts of apparently healthy individuals, patients with
benign lungdiseases (i.e., chronic obstructive pulmonary disease, tuber-
culosis, pneumonia and asthma), patients with other benign diseases
(i.e., acute and chronic inﬂammatory, liver, renal, autoimmune and
metabolic diseases) and patients with other malignant diseases. For
the malignant cohorts, clinical classiﬁcation (cTNM) or pathologic
classiﬁcation (pTNM) as well as Union for International Cancer Control
(UICC) stagingwas obligatory, with the number of metastases andmet-
astatic sites recorded. The date of sampling, date of primary diagnosis,histology results, demographic data and smoking habits (current
smoker, past smoker or never smoker) were also documented. Creati-
nine was measured in parallel to ProGRP, and the Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI) equation [33,34] was used
to calculate estimated glomerular ﬁltration rate (eGFR) to clarify the ef-
fect of renal insufﬁciency on ProGRP concentrations. A cutoff of
≥30 mL/min/1.73 m2 (CKD stage 3) was chosen because ProGRP levels
were found to be signiﬁcantly increased in patients with a CKD stage N3
(Supplementary Fig. S2). Statistical analysis was based on receiver
operating characteristic (ROC) curves and area under the curve (AUC)
calculations, with CIs based on the DeLong method [35]. Sensitivities
at 95% speciﬁcity, and speciﬁcity at 95% sensitivity, were also calculated.
4. Results
4.1. Technical assessment
The CV of the interlaboratory survey pooled samples ranged from
1.2% to 4.9%. The recovery of the ~30 pg/mL and ~200 pg/mL pooled
samples ranged from 94% to 106%. The recovery of the ~1500 pg/mL
sample varied more widely between laboratories, with an approximate
20% difference in recovery between the Bonn site (104%) and the
Amsterdam site (85%).
The intermediate imprecision for the three European human serum
pool samples and two control samples ranged from 2.2% (95% CI
1.8–2.7) to 6.0% (95% CI 4.7–8.4) CV (Supplementary Table S1), which
is comparable with data reported for the ARCHITECT ProGRP assay
(2.2–5.7% CV for serum and plasma) [23]. Within-run imprecision
ranged from 1.1% (95% CI 0.9–1.4) to 3.0% (95% CI 2.5–3.8) CV.
Sample stability was evaluated in nine samples from Amsterdam
and 10 samples from Bonn, with ProGRP concentrations ranging from
18 to 4259 pg/mL. Comparable recovery on the cobas® assay was
obtainedwith plasma and serum sampleswhen stored at room temper-
ature over 4 hours (median recovery at 4 hours: 98% in plasma, 102% in
SST and 99% in RST samples), or at 2–8 °C over 48 hours (median recov-
ery at 48 hours: 97% in plasma, 101% in SST and 101% in RST samples)
(Fig. 1). Good ProGRP stability was also demonstrated in plasma and
serum samples stored at −20 °C for 12 weeks (Supplementary
Fig. S3). Conversely, with the ARCHITECT assay, ProGRP in serum was
not well recovered over time (median recovery at 4 hours: 90% in SST
and 69% in RST samples), and results for plasma and serum samples
were not comparable, as previously reported [24].
The correlation between the ARCHITECT and the cobas® assays
using plasma samples up to ProGRP concentrations of 500 pg/mL is
shown in Fig. 2a. The slope and intercept across all sites combined was
1.02 (95% CI 0.96–1.08) and−2.72 pg/mL (95% CI−5.22–0.66), respec-
tively, with a correlation coefﬁcient of 0.96 (Supplementary Table S2).
Similar ﬁndings were reported for all sites across the entire measuring
range of 3–5000 pg/mL (data not shown). Across all sites, the relation-
ship between serum and plasma samples on the cobas® assay was
given by a slope of 0.93 (95% CI 0.89–0.98) and an intercept of
2.35 pg/mL (95% CI−0.21–4.60), with a correlation coefﬁcient of 0.97
for ProGRP concentrations up to 500 pg/mL (Fig. 2b). The slope for the
matrix comparison at the Barcelona site was signiﬁcantly higher than
the other sites. The reason for this is unknown but is not considered to
be clinically relevant and highlights the variability of the assay in the
ﬁeld. Comparable results were obtained for the correlation between
the Fujirebio and the cobas® assays using serum samples up to ProGRP
concentrations of 500pg/mL (Fig. 2c). Across all sites, the slopewas 1.33
(95% CI 1.15–1.47) and the intercept was −4.18 pg/mL (95% CI
−10.50–2.95), with a correlation coefﬁcient of 0.84.
4.2. Clinical assessment
Sample numbers from each patient cohort, and for each site, are
shown in Table 1. The reference range cohort consisted of 1085
Room temperature 2–8°C
Re
co
ve
ry
 (%
)
120
100
80
60
40
0 1 2 3 4
Time (hours)
cobas®
ARCHITECT
Re
co
ve
ry
 (%
)
120
100
80
60
40
0 3 6 24 48
Time (hours)
cobas®
ARCHITECT
Re
co
ve
ry
 (%
)
120
100
80
60
40
0 1 2 3 4
Time (hours)
cobas®
ARCHITECT
Re
co
ve
ry
 (%
)
120
100
80
60
40
0 3 6 24 48
Time (hours)
cobas®
ARCHITECT
Re
co
ve
ry
 (%
)
120
100
80
60
40
0 1 2 3 4
Time (hours)
cobas®
ARCHITECT
Re
co
ve
ry
 (%
)
120
100
80
60
40
0 3 6 24 48
Time (hours)
cobas®
ARCHITECT
Plasma (K2-EDTA) samples (n = 19)
SST samples (n = 19)
RST samples (n = 9)
A B
C D
E F
Fig. 1.Median ProGRP recovery from patient samples taken in Amsterdam (n=9) and Bonn (n=10), incubated at room temperature over 4 hours (A, C, E) or at 2–8 °C over 48 hours (B,
D, F) and measured on the cobas® or ARCHITECT instruments.
391C.M. Korse et al. / Clinica Chimica Acta 438 (2015) 388–395apparently healthy individuals with a mean age of 48 years (standard
deviation [SD] 16 years). The NSCLC cohort included 852 patients with
a mean age of 64 years (SD 12 years) and the SCLC cohort consisted of
207 patients with a mean age of 62 years (SD 11 years).
In the reference range cohort, 95th percentile ProGRP concentra-
tions were 68 pg/mL (95% CI 63.7–74.5) in Li-Heparin plasma,
60 pg/mL (95% CI 55.8–65.3) in EDTA plasma and 66 pg/mL (95% CI
62.4–72.6) in serum samples (Fig. 3). These data were comparable
with the reference range values on the ARCHITECT assay (63 pg/mLserum; 65 pg/mL EDTA plasma) [36] but higher than those reported
on the Fujirebio assay (43 pg/mL in serum) [37]. No signiﬁcant differ-
ence in median ProGRP concentration was observed between the
European and Chinese sites.
ProGRP showed good differential diagnosis between SCLC and
NSCLC, with an AUC of 0.90 (95% CI 0.87–0.93) with 78.3% sensitivity
at 95% speciﬁcity in the NSCLC cohort. The distribution of ProGRP is
shown in Fig. 4. No clinically relevant between-site effects were
observed within the NSCLC and SCLC cohorts across Europe and China,
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in the Chinese sites (data not shown). No clinically relevant effect of age,
gender or smoking habits on ProGRP concentrations was noted
(data not shown). A clinical differentiation cutoff for separating SCLC
(n= 207) from NSCLC (n= 852) was calculated as 84 pg/mL (95% CI
76.9–98.8), based on 95% speciﬁcity in the NSCLC cohort.
ProGRP values differed in samples from patients with limited
versus extensive SCLC (median 351 pg/mL vs. 757 pg/mL, respectively;
p= 0.0023) (Supplementary Fig. S4). At a ﬁxed speciﬁcity of 95% in the
NSCLC cohort, the sensitivity for limited-stage SCLC versus NSCLC was
71.7% (AUC of 85.6; 95% CI 80.3–90.9) and for extensive-stage SCLC
was 83.5% (AUC of 93.0; 95% CI 89.8–96.3). In patients with SCLC, a
correlation between UICC disease stage and ProGRP levels was appar-
ent, although the sample sizes of patients with stage I and II SCLC
were small (data not shown). ProGRP concentrations across all sites
were low in patientswith benign diseaseswhen excluding renal disease
(median 38 pg/mL), and in patients with other malignancies when
excluding renal disease, MCT or NET of the lung (median 40 pg/mL).
ProGRP showed even greater differential diagnosis between SCLC and
NSCLC in patients at the two Chinese sites (AUC 0.94 [95% CI
0.89–0.99]; 83.8% sensitivity at 95% speciﬁcity) compared with the
three European sites (AUC 0.89 [95% CI 0.85–0.92]; 76.9% sensitivity at
95% speciﬁcity in the NSCLC cohort), although this was not statistically
signiﬁcant, possibly owing to the smaller sample size of the Chinese
cohort (Fig. 5).5. Discussion
This multicenter evaluation of the Elecsys® ProGRP assay
showed good imprecision, stability and speciﬁcity across a number of
European and Chinese sites. Intermediate imprecision values ranged
from 2.2% to 6.0% CV and were comparable with data reported on the
ARCHITECT ProGRP assay [23]. Within-run imprecision ranged from
1.1% to 3.0% CV. Of note, the Elecsys® ProGRP assay performed equiva-
lently in EDTA plasma and serum samples, with recovery maintained
across a range of storage conditions. Archival samples are not always
believed to be as reliable as fresh samples, but our data demonstrated
that ProGRP remained stable in both archival and fresh tissues. In
contrast, the recovery of ProGRP in serum decreased over time with
the ARCHITECT assay, and differing results were obtained with plasma
and serum samples, as previously reported [24].
Stability issues reported with serum samples analyzed on the
ARCHITECT assay were thought to be partially due to thrombin within
the serum samples, and plasma was identiﬁed as the preferred source
material [24]. The greater stability of the Elecsys® ProGRP assay in
serum, relative to the ARCHITECT assay, most likely relates to the
antibody-binding sites on the ProGRP peptide. The two monoclonal
antibodies in the Elecsys® ProGRP assay bind to epitopes that are
relatively resistant to endoproteolytic cleavage [16,17,26], whereas the
twomonoclonal capture antibodies in the ARCHITECT assay bind direct-
ly next to the thrombin-cleavage site (Supplementary Fig. S1).
The ARCHITECT and cobas® assays showed good correlation in
plasma across all sites up to ProGRP concentrations of 500 pg/mL
(slope 1.02, intercept−2.72 pg/mL) and across the entire measuring
range. Good correlation between serum and plasma was also demon-
strated on the cobas® assay, up to ProGRP concentrations of
500 pg/mL (slope 0.93, intercept 2.35 pg/mL), and across the entire
measuring range. Therewas also good correlation between the Fujirebio
and cobas® assays in serum samples across all sites up to ProGRP
concentrations of 500 pg/mL (slope 1.33, intercept −4.18 pg/mL).
Notably, samples from laboratories in Bonn and Barcelona did not
evenly cover the measuring range, with most samples in the region
below 500 pg/mL ProGRP. The difference between the ARCHITECT and
cobas® assays over the whole measuring range is smaller than that
reported for the correlation between the ARCHITECT and Fujirebio
Table 1
Sample numbers for each cohort from each site.
Cohort Kiel Amsterdam Barcelona Bonn PUMCH Xuanwu All
Healthy N 698 100 100 41 71 75 1085
Mean age, years (SD) 49 (17) 51 (13) 51 (7) 38 (12) 39 (15) 38 (12) 48 (16)
Male/female, n 336/362 50/50 33/67 4/37 31/40 24/51 478/607
SCLC N – 67 68 35 22 15 207
Mean age, years (SD) – 61 (10) 65 (12) 62 (10) 62 (13) 60 (8) 62 (11)
Male/female, n – 38/29 53/15 23/12 17/5 12/3 143/64
Limited/extensive disease, n – 38/29 26/42 14/21 9/13 5/10 92/115
NSCLC N – 397 316 44 42 53 852
Mean age, years (SD) – 62 (12) 67 (11) 62 (10) 60 (10) 65 (11) 64 (12)
Male/female, n – 243/154 229/87 29/15 25/17 28/25 554/298
Adenocarcinoma, n – 144 183 15 28 28 398
Squamous-cell carcinoma, n – 130 91 12 10 20 263
NSCLC NOS, n – 106 32 16 4 4 162
Large-cell carcinoma, n – 17 10 1 – 1 29
Benign lung disease N – – 28 11 17 41 97
Mean age, years (SD) – – 61 (13) 61 (9) 44 (15) 57 (14) 56 (15)
Male/female, n – – 16/12 3/8 7/10 24/17 50/47
Other benign disease N – – 72 74 16 15 177
Mean age, years (SD) – – 47(21) 57 (17) 44 (18) 62 (12) 52 (19)
Male/female, n – – 34/38 29/45 9/7 9/6 81/96
Thereof renal N – – 27 6 5 1 39
Other malignant disease N – 116 100 119 17 15 367
Mean age, years (SD) – 59 (13) 68 (13) 63 (12) 51 (14) 65 (11) 63 (13)
Male/female, n – 58/58 50/50 47/72 12/5 13/2 180/187
Thereof MCT N – 11 4 – – – 15
Thereof NET of the lung N – 13 8 – 1 – 22
NOS: not otherwise speciﬁed; MCT: medullary carcinoma of the thyroid; NET: neuroendocrine tumors.
393C.M. Korse et al. / Clinica Chimica Acta 438 (2015) 388–395ProGRP assays (slope 0.93, Passing–Bablok regression; correlation
coefﬁcient 0.99) [36].
The ProGRP reference range measured in apparently healthy
individuals on the Elecsys® ProGRP assay gave comparable results to
the reference range on the ARCHITECT assay [36]. Samples from
Barcelona and Bonn had slightly lower ProGRP concentrations than
the other sites.
ProGRP showed clear differential diagnosis between SCLC and
NSCLC in serum, with 78% sensitivity at 95% speciﬁcity in the NSCLC
cohort, as previously noted with the ARCHITECT ProGRP assay [16,17,0
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Fig. 3. Reference range distribution of ProGRP in serum and plasma samples fro21,36]. No clinically relevant differences between sites were noted in
the NSCLC and SCLC cohorts. In addition, no clinically relevant effects
of age, gender or smoking habits were observed. This is the ﬁrst evalua-
tion of a ProGRP assay speciﬁcally in Chinese patients and demonstrates
the reproducibility of results among different ethnicities.
Although the number of patients with early-stage SCLC was small,
ProGRP concentrations were higher in patients with extensive versus
limited SCLC, as previously reported [25,38]. A correlation between
tumor size (according to UICC stage) and ProGRP concentration was
also noted. As expected, ProGRP concentrations were low in patientsn = 71 n = 698 n = 698 n = 71 n = 75
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394 C.M. Korse et al. / Clinica Chimica Acta 438 (2015) 388–395with NSCLC, benign lung disease, other benign diseases or other malig-
nancies (excluding renal disease, MCT and NET of the lung). Because
elevated ProGRP levels are only found in NET originating from the
lung or from an unknown primary site [22], ProGRP may be a useful
diagnostic tool in locating the primary site of unknown NETs. ProGRP
showed good differential diagnosis between SCLC and NSCLC in serum
from patients with eGFR ≥30 mL/min/1.73 m2 (CKD stage 3) at all
European and Chinese sites, but care should be taken in interpreting
ProGRP results in patients with eGFR b30 mL/min/1.73 m2.
The clinical utility of ProGRP as a biomarker to distinguish SCLC from
other lung cancers has been established in a number of studies [12,16,
20,21,39–42]. In a meta-analysis of 5146 patients enrolled in 11 clinical
trials, the sensitivity and speciﬁcity of ProGRP in diagnosing SCLC was
0.716 (95% CI 0.688–0.743) and 0.921 (95% CI 0.909–0.932), respective-
ly [40]. The clinical performance of the Elecsys®ProGRP assay is fully in-
line with these results. Data from this multicenter evaluation of the
Elecsys® ProGRP assay demonstrate that ProGRP is a speciﬁc tumor0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
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0.8
1.0
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Fig. 5. ROC curves of ProGRP (eGFR ≥30 mL/min/1.73 m2) for SCLC versus NSCLC for
European and Chinese sites. Europe SCLC (n = 170), NSCLC (n = 757); China SCLC
(n= 37), NSCLC (n= 95).marker for SCLC, which supports differential diagnosis in lung cancer.
The increased stability of the Elecsys® ProGRP assay in serum is a
clear beneﬁt for routine use in clinical laboratories, because serum is a
preferred sample material in tumor-marker testing. An investigation
into the use of ProGRP in treatment monitoring is currently ongoing,
as well as measurement and analysis of other tumor markers
(CEA, NSE, CYFRA 21–1) in the same collectives.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2014.09.015.
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